Glutathione in multiple sclerosis

British Journal of Biomedical Science

Volumn 70, Issue 2, 2013, Pages 75-79

  Ferreira, B ^a   Mendes, F ^a   Osorio N ^a   Caseiro, A ^a   Gabriel, A ^a   Valado, A ^a  

^a POLYTECHNIC INSTITUTE OF COIMBRA   (Portugal)

Author keywords

Glutathione; Glutathione peroxidase; Glutathione reductase; Multiple sclerosis; Oxidative stress

Indexed keywords

4 HYDROXYNONENAL; ACETYL COENZYME A; ACROLEIN; ADENOSINE TRIPHOSPHATE; CATALASE; DIHYDROLIPOATE; FREE RADICAL; FUMARIC ACID DIMETHYL ESTER; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; PEROXIDE; PYRUVIC ACID; REACTIVE NITROGEN SPECIES; REACTIVE OXYGEN METABOLITE; SINGLET OXYGEN; SUPEROXIDE DISMUTASE; THIOCTIC ACID; UBIQUINONE; URIC ACID;

AEROBIC METABOLISM; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; APOPTOSIS; ASTROCYTE; CELL DAMAGE; CELL DEATH; CELL PROTECTION; CELL RESPIRATION; CHROMATOPHORE; CONCENTRATION (PARAMETERS); CYTOTOXICITY; DISABILITY SEVERITY; DISEASE DURATION; EXTRAVASATION; GRAY MATTER; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUNTINGTON CHOREA; LIPID PEROXIDATION; LYMPHOCYTE; MITOCHONDRIAL MEMBRANE POTENTIAL; MONOCYTE; MULTIPLE SCLEROSIS; NECROSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OXIDATION REDUCTION POTENTIAL; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PARKINSON DISEASE; PHAGOCYTOSIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIGNAL TRANSDUCTION; TIGHT JUNCTION; WHITE MATTER;

EID: 84881074991     PISSN: 09674845     EISSN: None     Source Type: Journal    
DOI: 10.1080/09674845.2013.11669939     Document Type: Review

References (27)

1. Pampliega O, Domercq M, Soria FN, Villoslada P, Rodriguez-Antiguedad A, Matute C. Increased expression of cystine/glutamate antiporter in multiple sclerosis. J Neuroinflammation 2011; 8: 63.
2. Faraco G, Cavone L, Chiarugi A. The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol Med 2011; 17 (5-6): 442-7.
3. Mossberg N, Movitz C, Hellstrand K, Bergstrom T, Nilsson S, Andersen O. Oxygen radical production in leukocytes and disease severity in multiple sclerosis. J Neuroimmunol 2009; 213 (1-2): 131-4.
4. Haider L, Fischer MT, Frischer JM et al. Oxidative damage in multiple sclerosis lesions. Brain 2011; 134 (Pt 7): 1914-24.
5. Tasset I, Aguera E, Sanchez-Lopez F et al. Peripheral oxidative stress in relapsing-remitting multiple sclerosis. Clin Biochem 2012; 45 (6): 440-4.
6. Choi IY, Lee SP, Denney DR, Lynch SG. Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T. Mult Scler 2011; 17 (3): 289-96.
7. Di Giuseppe D, Ulivelli M, Bartalini S et al. Regulation of redox forms of plasma thiols by albumin in multiple sclerosis after fasting and methionine loading test. Amino Acids 2010; 38 (5): 1461-71.
8. Srinivasan R, Ratiney H, Hammond-Rosenbluth KE, Pelletier D, Nelson SJ. MR spectroscopic imaging of glutathione in the white and gray matter at 7 T with an application to multiple sclerosis. Magn Reson Imaging 2010; 28 (2): 163-70.
9. Ortiz GG, Macias-Islas MA, Pacheco-Moises FP et al. Oxidative stress is increased in serum from Mexican patients with relapsing-remitting multiple sclerosis. Dis Markers 2009; 26 (1): 35-9.
10. Artemiadis AK, Anagnostouli MC, Alexopoulos EC. Stress as a risk factor for multiple sclerosis onset or relapse: a systematic review. Neuroepidemiology 2011; 36 (2): 109-20.
11. Miller E, Mrowicka M, Zolynski K, Kedziora J. Oxidative stress in multiple sclerosis (in Polish). Pol Merkur Lekarski 2009; 27 (162): 499-502.
12. Shi R, Rickett T, Sun W. Acrolein-mediated injury in nervous system trauma and diseases. Mol Nutr Food Res 2011; 55 (9): 1320-31.
13. Mossberg N. Respiratory burst and severity of demyelinating disease. Univerity of Gothenburg; 2010.
14. Arancibia S, Rios C, Crisostomo N et al. Oxidative stress and neurodegenerative disease. In: Chang RC ed. Neurodegenerative diseases: Processes, prevention, protection and monitoring. In Tech, 2011.
15. Lanza C, Morando S, Voci A et al. Neuroprotective mesenchymal stem cells are endowed with a potent antioxidant effect in vivo. J Neurochem 2009; 110 (5): 1674-84.
16. Ursini F, Maiorino M, Gregolin C. The selenoenzyme phospholipid hydroperoxide glutathione peroxidase. Biochim Biophys Acta 1985; 839 (1): 62-70.
17. Katona PG, McLean M, Dighton DH, Guz A. Sympathetic and parasympathetic cardiac control in athletes and nonathletes at rest. J Appl Physiol 1982; 52 (6): 1652-7.
18. Armstrong D. Free radical and antioxidant protocols. Introduction. Methods Mol Biol 1998; 108: v-viii.
19. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 1992; 59 (5): 1609-23.
20. Erratum in J Neurochem 2012; 120 (5): 850.
21. Salinthone S, Yadav V, Bourdette DN, Carr DW. Lipoic acid: a novel therapeutic approach for multiple sclerosis and other chronic inflammatory diseases of the CNS. Endocr Metab Immune Disord Drug Targets 2008; 8 (2): 132-42.
22. Scannevin RH, Chollate S, Jung MY et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther 2012; 341 (1): 274-84.
23. Krotenko NV, Alifirova VM, Ivanova SA. Parameters of antioxidant protection in multiple sclerosis (in Russian). Zh Nevrol Psikhiatr Im S S Korsakova 2009; 109 (7 Suppl 2): 53-6.
24. Pasichna EP, Morozova RP, Donchenko HV, Vinychuk SM, Kopchak OO. Lipid peroxidation and antioxidant defence enzyme activity in multiple sclerosis (in Ukrainian). Ukr Biokhim Zh 2007; 79 (5): 165-74.
25. Tajouri L, Mellick AS, Ashton KJ et al. Quantitative and qualitative changes in gene expression patterns characterize the activity of plaques in multiple sclerosis. Brain Res Mol Brain Res 2003; 119 (2): 170-83.
26. Mirshafiey A, Mohsenzadegan M. Antioxidant therapy in multiple sclerosis. Immunopharmacol Immunotoxicol 2009; 31 (1): 13-29.
27. Calabrese V, Raffaele R, Cosentino E, Rizza V. Changes in cerebrospinal fluid levels of malondialdehyde and glutathione reductase activity in multiple sclerosis. Int J Clin Pharmacol Res 1994; 14 (4): 119-23.